Q. A 45-year-old woman with a background in biomedical research is keen on understanding the lipid metabolism, especially in relation to hypercholesterolemia. She is particularly interested in the drug evolocumab, which she knows is a PCSK9 inhibitor. She wants to know the specific role PCSK9 plays in lipoprotein metabolism. What is the most appropriate answer?